Cellectar, Inc., a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The companyï¿½s product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignant cells. Cellectar, Inc. was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin.